



Cancer Genetics Publications

SurePrint Comparative Genome Hybridization

Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, and Kim TY. **Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability.** *Nucleic Acids Res.* (2016) 44:2:558-572 doi: 10.1093/nar/gkv933. [Abstract](#)

Bettio D, Venci A, Achille V, Alloisio M, and Santoro A. **Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report.** *Exp Ther Med* (2016) 11(1): 98-100. [Abstract](#)

Li MM, Monzon FA, Biegel JA, Jobanputra V, Laffin JJ, Levy B, Leon A, Miron P, Rossi MR, Toruner G, Alvarez K, Doho G, Dougherty MJ, Hu X, Kash S, Streck D, Znoyko I, Hagenkord JM, and Wolff DJ. **A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays.** *Cancer Genetics* (2015) 208:525–536. doi: 10.1016/j.cancer-gen.2015.08.002. [Abstract](#)

Frattini A, Fabbri M, Valli R, Paoli ED, Montalbano G, Gribaldo L, Pasquali F, and Maserati E. **High variability of genomic instability and gene expression profiling in different HeLa clones.** *Sci Rep.* (2015) 5: 15377. [Abstract](#)

Jour G, Liu Y, Ricciotti R, Pritchard C, and Hoch B. **Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon.** *Hum Pathol.* (2015) 46(9): 1398–1404. doi:10.1016/j.humpath.2015.05.018. [Abstract](#)

Qian J, Zou Y, Wang J, Zhang B, and Massion P. **Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung.** *Genom Data* (2015) 5:272-274. doi:10.1016/j.gdata.2015.06.014 [Abstract](#)

Frattini A, Fabbri M, Valli R, Paoli ED, Montalbano G, Gribaldo L, Pasquali F, and Maserati E. **High variability of genomic instability and gene expression profiling in different HeLa clones.** *Sci Rep.* (2015) 5: 15377. doi: 10.1038/srep15377. [Abstract](#)

Bodelon C, Vinokurova S, Sampson JN, Boon JA, Walker JL, Horswill MA, Korthauer K, Schifman M, Sherman ME, Zuna RE, Mitchell J, Zhang X, Boland JF, Chaturvedi AK, Dunn T, Newton MA, Ahlquist P, Wang SS, and Wentzensen N. **Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.** *Carcinogenesis* (2015) doi: 10.1093/carcin/bgv171. [Abstract](#)

Valli R, Bernardi FD, Frattini A, Volpi L, Bignami M, Facchetti F, Pasquali F, Castelnuovo P, and Maserati E. **Comparative Genomic Hybridization on Microarray (a-CGH) in Olfactory Neuroblastoma: Analysis of Ten Cases and Review of the Literature.** *Genes, Chromosomes & Cancer* (2015) 54:771–775. [Abstract](#)



SureSelect Target Enrichment

Shirts BH, Casadei S, Jacobson AL, Lee MK, Gulsuner S, Bennett RL, Miller M, Hall SA, Hampel H, Hisama FM, Naylor LV, Goetsch C, Leppig K, Tait JF, Scroggins SM, Turner EH, Livingston R, Salipante SJ, King MC, Walsh T, and Pritchard CC. **Improving performance of multigene panels for genomic analysis of cancer predisposition.** *Genet Med.* (2016) Feb 4. doi: 10.1038/gim.2015.212. [Abstract](#)

Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE, Bader GD, Mills GB, Pe'er D, Moffat J, and Neel BG. **Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance.** *Cell* (2016) 164(1-2):293-309. doi: 10.1016/j.cell.2015.11.062. [Abstract](#)

Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, Gangat N, and Tefferi A. **Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.** *Blood Cancer J.* (2016) 15;6:e385. doi: 10.1038/bcj.2015.113. [Abstract](#)

Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, Rozen SG, Tan MH, Ang P, Ngeow J, and Lee ASG. **Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore.** *NPJ Genomic Medicine* 1: Article number: 15003 (2016) doi:10.1038/npjgenmed.2015.3.

HaloPlex^{HS} Target Enrichment

Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Féger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, and Delhommeau F. **Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.** *Nature Communications.* (2016) 7: 12475. DOI: 10.1038/ncomms12475. [Abstract](#)

Kock L, Wang YC, Revil T, Badescu D, Rivera B, Sabbaghian N, Wu M, Weber E, Sandoval C, Hopman SMJ, Merks JHM, Hagen JM, Bouts AHM, Plager DA, Ramasubramanian A, Forsmark L, Doyle

KL, Toler T, Callahan J, Engelenberg C, Soglio DBD, Priest JR, Ragoussis J, and Foulkes WD. **High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome.** *J Med Genet.* (2016) 53(1):43-52. doi: 10.1136/jmedgenet-2015-103428. [Abstract](#)

Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, Bories D, Marzac C, Fava F, Legrand O, Mohty M, Douay L and Delhommeau F. **Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.** *Leukemia* (2016) Mar 1. doi: 10.1038/leu.2016.31. [Abstract](#)

HaloPlex Target Enrichment

Thompson ER, Rowley SM, Li N, McInerney S, Devereux L, Wong-Brown MW, Trainer AH, Mitchell G, Scott RJ, James PA, and Campbell IG. **Panel testing for familial breast cancer: calibrating the tension between research and clinical care.** *J Clin Oncol.* (2016) Jan 19. pii: JCO637454. [Abstract](#)

Petersen AH, Aagaard MM, Nielsen HR, Steffensen KD, Waldstrøm M and Bojesen A. **Post-mortem testing: germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.** *Eur J Hum Genet.* (2016) Jan 6. doi: 10.1038/ejhg.2015.268. [Abstract](#)

Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, and Arihiro K. **Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma.** *Cancer Cell.* (2016) 29(2):229-40. doi: 10.1016/j.ccell.2015.12.012. [Abstract](#)

Moens LNJ, Falk-Sörqvist E, Ljungström V, Mattsson J, Sundström M, Fleur LL, Mathot L, Micke P, Nilsson M, and Botling J. **HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples.** *J Mol Diagn.* (2015) 17(6):729-39. doi: 10.1016/j.jmoldx.2015.06.009. [Abstract](#)

ClearSeq Comprehensive Cancer Research Panel

Spencer DH, Tyagi M, Vallania F, Bredemeyer AJ, Pfeifer JD, Mitra RD, and Duncavage EJ. **Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data.** *J Mol Diagn.* (2014) 16(1):75-88. doi: 10.1016/j.jmoldx.2013.09.003. [Abstract](#)

Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, and Duncavage EJ. **Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens.** *J Mol Diagn.* (2013) 15(5):623-33. doi: 10.1016/j.jmoldx.2013.05.004. [Abstract](#)

Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, Kulkarni S, Pfeifer JD, and Duncavage EJ. **Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.** *J Mol Diagn.* (2013) 15(1):81-93. doi: 10.1016/j.jmoldx.2012.08.001. [Abstract](#)

ClearSeq AML Research Panel

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, and Arber DA. **Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.** *Mod Pathol.* (2015) 28(5):706-14. doi: 10.1038/modpathol.2014.160. [Abstract](#)

SureSelect RNA Seq

Guo Y, Sheng Q, Li J, Ye F, Samuels DC, and Shyr Y. **Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data.** *PLoS One* (2013) 8(8):e71462. doi: 10.1371/journal.pone.0071462. [Abstract](#)

Cieslik M, Chugh R, Wu YM, Wu M, Brennan C, Lonigro R, Su F, Wang R, Siddiqui J, Mehra R, Cao X, Lucas D, Chinnaiyan AM, and Robinson D. **The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.** *Genome Res.* (2015) (9):1372-81. doi: 10.1101/gr.189621.115.

Kogenaru S, Qing Y, Guo Y, and Wang N. **RNA-seq and microarray complement each other in transcriptome profiling.** *BMC Genomics.* (2012) 13:629. doi: 10.1186/1471-2164-13-629. [Abstract](#)

SEQC/MAQC-III Consortium. **A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium.** *Nat Biotechnol.* (2014) (9):903-14. doi: 10.1038/nbt.2957. [Abstract](#)

SureSelect Methyl Seq

Lee EJ, Luo J, Wilson JM, and Shi H. **Analyzing the cancer methylome through targeted bisulfite sequencing.** *Cancer Lett.* (2013) 340(2):171-8. doi: 10.1016/j.canlet.2012.10.040. [Abstract](#)

Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, and Milani L. **In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes.** *Nucleic Acids Res.* (2013) 41(6):e72. doi: 10.1093/nar/gks1467. [Abstract](#)

Hing B, Ramos E, Braun P, McKane M, Jancic D, Tamashiro KL, Lee RS, Michaelson JJ, Druley TE, and Potash JB. **Adaptation of the targeted capture Methyl-Seq platform for the mouse genome identifies novel tissue-specific DNA methylation patterns of genes involved in neurodevelopment.** *Epigenetics* (2015) 10(7):581-96. doi: 10.1080/15592294.2015.1045179. [Abstract](#)

Sánchez-Martín FJ, Lindquist DM, Landero-Figueroa J, Zhang X, Chen J, Cecil KM, Medvedovic M, and Puga A. **Sex- and tissue-specific methylome changes in brains of mice perinatally exposed to lead.** *Neurotoxicology* (2015) 46:92-100. doi: 10.1016/j.neuro.2014.12.004. [Abstract](#)

FISH

Shapiro SG, Raghunath S, Williams C, Motsinger-Reif AA, Cullen JM, Liu T, Albertson D, Ruvolo M, Bergstrom Lucas A, Jin J, Knapp DW, Schiffman JD, and Breen M. **Canine urothelial carcinoma: genomically aberrant and comparatively**

relevant. *Chromosome Res.* (2015) 23(2):311-31. doi: 10.1007/s10577-015-9471-y. [Abstract](#)

TapeStation System

Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, Wilcox S, Tai L, Strasser A, and Herold MJ. **An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.** *Cell Rep.* (2015) 10(8):1422-32. doi: 10.1016/j.celrep.2015.02.002. [Abstract](#)

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JKV, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston R, Markowitz SD, and Willis JE. **Novel recurrently mutated genes in African American colon cancers.** *PNAS* (2015) 112: 1149 – 1154.

Kappler CS, Guest ST, Irish JC, Garrett-Mayer E, Kratche Z, Wilson RC, and Ethier SP. **Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer.** *Mol Oncol.* (2015) 9(2):527-43. doi: 10.1016/j.molonc.2014.10.006. [Abstract](#)

Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, Gulsuner S, Pritchard CC, Sanchez-Bonilla M, Delrow JJ, Basom RS, Forouhar M, Gyurkocza B, Schwartz BS, Neistadt B, Marquez R, Mariani CJ, Coats SA, Hofmann I, Lindsley RC, Williams DA, Abkowitz JL, Horwitz MS, King MC, Godley LA, and Shimamura A. **Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.** *Nat Genet.* (2015) 47(2):180-5. doi: 10.1038/ng.3177. [Abstract](#)

Quabius ES, Gorogh T, Fischer GS, Hoffmann AS, Gebhard M, Evert M, Beule A, Maune S, Knecht R, Ovari A, Durisin M, Hoppe F, Rocke C, Hedderich J, Ambrosch P, Hoffmann M. **The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma.** *Cancer Lett.* (2015) 357(1):339-45. doi: 10.1016/j.canlet.2014.11.043. [Abstract](#)

Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, Campanile A, Yew PY, Ganshert C, Fujioka T, Steinberg GD, O'Donnell PH, and Nakamura Y. **Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.** *Clin Cancer Res.* (2014) 20(24):6605-17. doi: 10.1158/1078-0432.CCR-14-0257. [Abstract](#)

Zhang FG, He ZY, and Wang Q. **Transcriptome profiling of the cancer and normal tissues from gastric cancer patients by deep sequencing.** *Tumour Biol.* (2014) 35(8):7423-7. doi: 10.1007/s13277-014-2003-0. [Abstract](#)

Trusted Answers. **Together.**

PR7000-0252
© Agilent Technologies, Inc. 2016
Printed in USA, September 7, 2016
5991-7397EN

LEARN MORE AT:
www.agilent.com/genomics

Find an Agilent customer center in your country:
www.agilent.com/genomics/contactus

U.S. and Canada
1-800-227-9770
agilent_inquiries@agilent.com

Europe
info_agilent@agilent.com

Asia Pacific
info_agilent@agilent.com

For Research Use Only. Not for use in diagnostic procedures.



Agilent Technologies